Canaccord Genuity Reaffirms Buy Rating for Ionis Pharmaceuticals
Analyst Gary Nachman from Canaccord Genuity has maintained a 'Buy' rating on Ionis Pharmaceuticals (IONS) with a price target of $85.00. This is in line with his previous recommendation, and he covers the Healthcare sector, focusing on stocks such as IONS, Jazz Pharmaceuticals, and Amgen.
Nachman's track record shows an average return of 0.6% and a success rate of 46.32% on recommended stocks according to TipRanks. This means that his predictions have been accurate nearly half the time, resulting in modest gains for investors who follow his recommendations.
In addition to Canaccord Genuity's 'Buy' rating, Ionis Pharmaceuticals also received a positive recommendation from H.C. Wainwright's Mitchell Kapoor. However, Goldman Sachs maintained a 'Hold' rating on IONS just ten days prior on September 14.